Evidence map›Paper›PMID 32963103›Full record

Trial reportNeurology2020

Neural effects of oxytocin and mimicry in frontotemporal dementia: A randomized crossover study.

Lindsay D Oliver, Chloe Stewart, Kristy Coleman, James H Kryklywy, Robert Bartha, Derek G V Mitchell, Elizabeth C Finger

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01937013 (Impact of Emotional Mimicry and Oxytocin on Frontotemporal Dementia), which is not on this map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01937013 phase2completednot on this map

Impact of Emotional Mimicry and Oxytocin on Frontotemporal Dementia

TypeinterventionalSponsorLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sRan2013 to 2017Enrolled52ConditionsFrontotemporal DementiaArmsIntranasal oxytocin, Saline Nasal Mist
3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Sex differences in neuromodulatory subcortical systems and their implications for Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Review
  4. Review
  5. Article
  6. Review
  7. New Approaches to the Treatment of Frontotemporal Dementia.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023
    Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Lindsay D OliverFrom the Graduate Program in Neuroscience (L.D.O., C.S., J.H.K.) and Department of Clinical Neurological Sciences (E.C.F.), Schulich School of Medicine and Dentistry, Robarts Research Institute (R.B., E.C.F.), and Brain and Mind Institute (D.G.V.M.), Department of Psychiatry and Department of Anatomy and Cell Biology, Western University, London; Campbell Family Mental Health Research Institute (L.D.O.), Centre for Addiction and Mental Health, Toronto; Parkwood Institute Research (K.C., E.C.F.), London, Ontario; and Department of Psychology (J.H.K.), University of British Columbia, Vancouver, Canada.
Chloe StewartFrom the Graduate Program in Neuroscience (L.D.O., C.S., J.H.K.) and Department of Clinical Neurological Sciences (E.C.F.), Schulich School of Medicine and Dentistry, Robarts Research Institute (R.B., E.C.F.), and Brain and Mind Institute (D.G.V.M.), Department of Psychiatry and Department of Anatomy and Cell Biology, Western University, London; Campbell Family Mental Health Research Institute (L.D.O.), Centre for Addiction and Mental Health, Toronto; Parkwood Institute Research (K.C., E.C.F.), London, Ontario; and Department of Psychology (J.H.K.), University of British Columbia, Vancouver, Canada.
Kristy ColemanFrom the Graduate Program in Neuroscience (L.D.O., C.S., J.H.K.) and Department of Clinical Neurological Sciences (E.C.F.), Schulich School of Medicine and Dentistry, Robarts Research Institute (R.B., E.C.F.), and Brain and Mind Institute (D.G.V.M.), Department of Psychiatry and Department of Anatomy and Cell Biology, Western University, London; Campbell Family Mental Health Research Institute (L.D.O.), Centre for Addiction and Mental Health, Toronto; Parkwood Institute Research (K.C., E.C.F.), London, Ontario; and Department of Psychology (J.H.K.), University of British Columbia, Vancouver, Canada.
James H KryklywyFrom the Graduate Program in Neuroscience (L.D.O., C.S., J.H.K.) and Department of Clinical Neurological Sciences (E.C.F.), Schulich School of Medicine and Dentistry, Robarts Research Institute (R.B., E.C.F.), and Brain and Mind Institute (D.G.V.M.), Department of Psychiatry and Department of Anatomy and Cell Biology, Western University, London; Campbell Family Mental Health Research Institute (L.D.O.), Centre for Addiction and Mental Health, Toronto; Parkwood Institute Research (K.C., E.C.F.), London, Ontario; and Department of Psychology (J.H.K.), University of British Columbia, Vancouver, Canada.
Robert BarthaFrom the Graduate Program in Neuroscience (L.D.O., C.S., J.H.K.) and Department of Clinical Neurological Sciences (E.C.F.), Schulich School of Medicine and Dentistry, Robarts Research Institute (R.B., E.C.F.), and Brain and Mind Institute (D.G.V.M.), Department of Psychiatry and Department of Anatomy and Cell Biology, Western University, London; Campbell Family Mental Health Research Institute (L.D.O.), Centre for Addiction and Mental Health, Toronto; Parkwood Institute Research (K.C., E.C.F.), London, Ontario; and Department of Psychology (J.H.K.), University of British Columbia, Vancouver, Canada.
Derek G V MitchellFrom the Graduate Program in Neuroscience (L.D.O., C.S., J.H.K.) and Department of Clinical Neurological Sciences (E.C.F.), Schulich School of Medicine and Dentistry, Robarts Research Institute (R.B., E.C.F.), and Brain and Mind Institute (D.G.V.M.), Department of Psychiatry and Department of Anatomy and Cell Biology, Western University, London; Campbell Family Mental Health Research Institute (L.D.O.), Centre for Addiction and Mental Health, Toronto; Parkwood Institute Research (K.C., E.C.F.), London, Ontario; and Department of Psychology (J.H.K.), University of British Columbia, Vancouver, Canada.
Elizabeth C FingerFrom the Graduate Program in Neuroscience (L.D.O., C.S., J.H.K.) and Department of Clinical Neurological Sciences (E.C.F.), Schulich School of Medicine and Dentistry, Robarts Research Institute (R.B., E.C.F.), and Brain and Mind Institute (D.G.V.M.), Department of Psychiatry and Department of Anatomy and Cell Biology, Western University, London; Campbell Family Mental Health Research Institute (L.D.O.), Centre for Addiction and Mental Health, Toronto; Parkwood Institute Research (K.C., E.C.F.), London, Ontario; and Department of Psychology (J.H.K.), University of British Columbia, Vancouver, Canada. Elizabeth.Finger@lhsc.on.ca.
Centre for Addiction and Mental Health · CAMental Health Research Institute · AUParkwood Institute · CA

Funding

CIHR 286763
6 · The paper itself

Abstract

objectiveTo determine whether intranasal oxytocin, alone or in combination with instructed mimicry of facial expressions, would augment neural activity in patients with frontotemporal dementia (FTD) in brain regions associated with empathy, emotion processing, and the simulation network, as indexed by blood oxygen-level dependent (BOLD) signal during fMRI.

methodsIn a placebo-controlled, randomized crossover design, 28 patients with FTD received 72 IU intranasal oxytocin or placebo and then completed an fMRI facial expression mimicry task.

resultsOxytocin alone and in combination with instructed mimicry increased activity in regions of the simulation network and in limbic regions associated with emotional expression processing.

conclusionsThe findings demonstrate latent capacity to augment neural activity in affected limbic and other frontal and temporal regions during social cognition in patients with FTD, and support the promise and need for further investigation of these interventions as therapeutics in FTD. CLINICALTRIALSGOV IDENTIFIER: NCT01937013. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that a single dose of 72 IU intranasal oxytocin augments BOLD signal in patients with FTD during viewing of emotional facial expressions.

Indexed as

EmotionsFacial ExpressionAdministration, IntranasalAgedBrainCross-Over StudiesEmpathyFemaleFrontotemporal DementiaFunctional NeuroimagingHumansImitative BehaviorMagnetic Resonance ImagingMaleMiddle AgedOxytocicsOxytocicsOxytocin

Identifiers

PMID32963103
PMCPMC7713736
OpenAlexW3089151448

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.